ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Janssen Biotech, an arm of Johnson & Johnson, will pay Genmab $55 million up front for access to the monoclonal antibody daratumumab and a backup antibody. As part of the deal, J&J will invest roughly $80 million in the Danish biotech company. Janssen will also take on development costs for daratumumab, including paying for ongoing Phase I/II clinical trials in patients with multiple myeloma. Daratumumab binds to CD38, a protein on the surface of several kinds of immune cells.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X